M
M. Engelhard
Publications - 3
Citations - 4311
M. Engelhard is an academic researcher. The author has contributed to research in topics: Medicine & Ann Arbor staging. The author has an hindex of 1, co-authored 1 publications receiving 4132 citations.
Papers
More filters
Journal Article
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more
TL;DR: The international index and the age-adjusted international index should be used in the design of future therapeutic trials in patients with aggressive non-Hodgkin's lymphoma and in the selection of appropriate therapeutic approaches for individual patients.
Journal ArticleDOI
Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular Lymphomas
Heike Horn,Vindi Jurinovic,Ellen Leich,Sabrina Kalmbach,Julia Bausinger,Annette M. Staiger,Katrin Kurz,Peter Möller,Heinz-Wolfram Bernd,Alfred C. Feller,Karoline Koch,Wolfram Klapper,Harald Stein,Martin-Leo Hansmann,F. Hartmann,Gabriel Scheubeck,Martin Dreyling,Wolfgang Hiddemann,Klaus Herfarth,M. Engelhard,Andreas Rosenwald,Eva Hoster,German Ott +22 more
TL;DR: Deletions in chromosomes 1p, 6q, and 17p predicted clinical outcome of patients with SFL in the entire cohort, while only deletions in chromosome 1p retained its negative prognostic impact in R-CHOP–treated SFL.
Journal ArticleDOI
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
Lorenz Thurner,Marita Ziepert,Chr. Berdel,Christian Schmidt,Peter Borchmann,Dominic Kaddu-Mulindwa,Andreas Viardot,Mathias Witzens-Harig,Judith Dierlamm,Mathias Haenel,Bernd Metzner,Gerald Wulf,Ulrich Keller,Norbert Frickhofen,Maike Nickelsen,Tobias Gaska,Frank Griesinger,Rolf Mahlberg,Reinhard Marks,Ofer Shpilberg,Hans-Walter Lindemann,Martin Soekler,Ludwig Fischer von Weikersthal,Michael G. Kiehl,E. Roemer,Martin Bentz,B. Krammer-Steiner,Ralf Ulrich Trappe,Peter de Nully Brown,Massimo Federico,Francesco Merli,M. Engelhard,Bertram Glass,N. Schmitz,L. Truemper,Moritz Bewarder,Franz Hartmann,Niels Murawski,Stephan Stilgenbauer,Andreas Rosenwald,Bettina Altmann,Heinz Schmidberger,Jochen Fleckenstein,Markus Loeffler,Viola Poeschel,Gerhard Heil +45 more
TL;DR: UNFOLDER (Unfavorable Young Low-Risk Densification of R-Chemo Regimens) is an international phase-3 trial in patients 18-60 years with aggressive B-cell lymphoma and intermediate prognosis defined by age-adjusted International Prognostic Index (aaIPI) of 0 and bulky disease (≥7.5 cm) or aaIPI of 1 as mentioned in this paper .